External Use Authorized ...
Becoming a substantial holder
Filed with ASX ·
6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL date of Annual General Meeting
- CLINUVEL develops proprietary ZEROKIN device
- Ceasing to be a substantial holder
- A decade of profitability provides foundation for CLINUVEL’s U.S. expansion
- CLINUVEL considers Nasdaq listing, ASX delisting
Later from Clinuvel Pharmaceuticals
- New CUV105 vitiligo cases presented to EADV
- Notice of Annual General Meeting/Proxy Form
- Change in substantial holding
- Application for quotation of securities - CUV
- Notification of cessation of securities - CUV
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals